ADXN
Income statement / Annual
Last year (2023), Addex Therapeutics Ltd's total revenue was $1.61 M,
an increase of 13.39% from the previous year.
In 2023, Addex Therapeutics Ltd's net income was -$10.56 M.
See Addex Therapeutics Ltd’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$1.61 M
|
$1.42 M
|
$2.92 M
|
$3.61 M
|
$2.76 M
|
$6.04 M
|
$499,894.00
|
$17,329.00
|
$40,301.00
|
$85,404.00
|
| Cost of Revenue |
$6.94 M |
$14.62 M |
$12.82 M |
$10.37 M |
$230,097.00 |
$144,169.00 |
$29,764.00 |
$17,329.00 |
$40,301.00 |
$85,404.00 |
| Gross Profit |
-$5.32 M |
-$13.20 M |
-$9.90 M |
-$6.76 M |
$2.53 M |
$5.90 M |
$470,130.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
-3.3 |
-9.28 |
-3.4 |
-1.87 |
0.92 |
0.98 |
0.94 |
0 |
0 |
0 |
| Research and Development
Expenses |
$2.75 M
|
$14.67 M
|
$12.84 M
|
$10.37 M
|
$12.45 M
|
$2.37 M
|
$841,308.00
|
$819,330.00
|
$761,217.00
|
$258,058.00
|
| General & Administrative
Expenses |
$7.20 M
|
$7.30 M
|
$5.14 M
|
$5.15 M
|
$4.27 M
|
$4.72 M
|
$2.20 M
|
$1.52 M
|
$1.57 M
|
$1.55 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$7.20 M
|
$7.30 M
|
$5.14 M
|
$5.15 M
|
$4.27 M
|
$4.72 M
|
$2.20 M
|
$1.52 M
|
$1.57 M
|
$1.55 M
|
| Other Expenses |
$0.00 |
-$22,521.00 |
$444,000.00 |
$336,676.00 |
$648,165.00 |
$382,993.00 |
$197,669.00 |
$799,702.00 |
$311,823.00 |
-$9,441.00 |
| Operating Expenses |
$11.89 M |
$21.94 M |
$18.42 M |
$15.86 M |
$17.37 M |
$7.47 M |
$3.24 M |
$3.14 M |
$2.64 M |
$1.80 M |
| Cost And Expenses |
$11.89 M |
$21.94 M |
$18.42 M |
$15.86 M |
$17.37 M |
$7.47 M |
$3.24 M |
$3.14 M |
$2.64 M |
$1.80 M |
| Interest Income |
$63,964.00 |
$29,251.00 |
$5,322.00 |
$35,305.00 |
$36,874.00 |
$85,866.00 |
$0.00 |
$27.00 |
$39,860.00 |
$1,586.00 |
| Interest Expense |
$21,607.00 |
$48,897.00 |
$63,012.00 |
$69,502.00 |
$128,518.00 |
$220,173.00 |
$45,350.00 |
$6,924.00 |
$152,210.00 |
$0.00 |
| Depreciation &
Amortization |
$305,952.00
|
$323,144.00
|
$347,613.00
|
$378,754.00
|
$333,844.00
|
$2,937.00
|
$15,249.00
|
$25,761.00
|
$25,878.00
|
$110,135.00
|
| EBITDA |
-$10.23 M
|
-$20.23 M
|
-$14.94 M
|
-$12.41 M
|
-$14.32 M
|
-$1.51 M
|
-$3.22 M
|
-$3.12 M
|
-$2.61 M
|
-$1.71 M
|
| EBITDA Ratio |
-6.34 |
-14.18 |
-5.2 |
-3.27 |
-5.15 |
-0.24 |
-6.44 |
-179.79 |
-64.89 |
-19.98 |
| Operating Income Ratio
|
-6.37
|
-14.43
|
-5.32
|
-3.39
|
-5.37
|
-0.24
|
-6.47
|
-180.6
|
-95.98
|
-21.04
|
| Total Other
Income/Expenses Net |
-$274,928.00
|
-$284,006.00
|
$154,003.00
|
-$615,325.00
|
-$176,447.00
|
-$220,173.00
|
-$45,350.00
|
-$19,789.00
|
-$1.56 M
|
$748,346.00
|
| Income Before Tax |
-$10.56 M |
-$20.80 M |
-$15.35 M |
-$12.86 M |
-$14.78 M |
-$1.64 M |
-$3.28 M |
-$3.15 M |
-$4.20 M |
-$1.77 M |
| Income Before Tax Ratio
|
-6.54
|
-14.63
|
-5.26
|
-3.56
|
-5.35
|
-0.27
|
-6.56
|
-181.74
|
-104.32
|
-20.78
|
| Income Tax Expense |
$0.00 |
$123,910.00 |
$116,377.00 |
$207,762.00 |
$429,009.00 |
$1.00 |
$0.00 |
$6,924.00 |
$152,210.00 |
-$21,678.00 |
| Net Income |
-$10.56 M |
-$20.80 M |
-$15.35 M |
-$12.86 M |
-$14.78 M |
-$1.64 M |
-$3.28 M |
-$3.15 M |
-$4.20 M |
-$1.77 M |
| Net Income Ratio |
-6.54 |
-14.63 |
-5.26 |
-3.56 |
-5.35 |
-0.27 |
-6.56 |
-181.74 |
-104.32 |
-20.78 |
| EPS |
-0.14 |
-0.46 |
-0.45 |
-0.48 |
-0.56 |
-0.0706 |
-0.25 |
-0.28 |
-0.39 |
-0.18 |
| EPS Diluted |
-0.14 |
-0.46 |
-0.45 |
-0.48 |
-0.56 |
-0.0706 |
-0.25 |
-0.28 |
-0.39 |
-0.18 |
| Weighted Average Shares
Out |
$74.31 M
|
$45.18 M
|
$34.12 M
|
$26.68 M
|
$26.43 M
|
$23.29 M
|
$12.94 M
|
$11.41 M
|
$10.85 M
|
$9.98 M
|
| Weighted Average Shares
Out Diluted |
$74.31 M
|
$45.18 M
|
$34.12 M
|
$26.68 M
|
$26.43 M
|
$23.29 M
|
$12.94 M
|
$11.41 M
|
$10.85 M
|
$9.98 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
